Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients | Zendy

AI Assistant Blog Pricing

Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.